Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Italy's Civil Protection officials said the quake, which struck at 3:19 a.m., was part of a swarm of some 1,000 tremors, most of them barely perceptible, linked to Etna's volcanic eruption this week. Italy's national seismology institute said the quake had a magnitude of 4.8 on the open-ended Richter scale and 4.9 on the moment magnitude scale, which relates to the amount the ground slips. It struck north of Catania, the largest city in the eastern part of the Mediterranean island, but no damage or injuries were reported there. The quake opened up cracks in homes in several towns, sending chunks of concrete debris tumbling to the ground. It toppled a Madonna statue in a church in Santa Venerina and broke up sidewalks and a stretch of highway, forcing it to close. Many people spent the hours after the quake sleeping in their cars. In the town of Piano d'Api, firefighters removed cracked stucco from the bell tower of the damaged Santa Maria della Misericordia church. Italy's culture ministry said the quake damage to churches was being tallied by experts. "Etna remains a dangerous volcano, and this country of ours is unfortunately fragile," government undersecretary Vito Crimi said as he reported 10 people injured. The most seriously injured was a 70-year-old man who fractured ribs and was undergoing surgery for chest injuries. A 71-year-old patient was being kept in hospital for observation, while others were treated and released, the Italian news agency ANSA reported. Additionally, 18 other people went to local hospitals suffering from panic attacks or shock, news reports said. One 80-year-old man was safely extracted from the rubble of his home, ANSA said, while a woman told state radio that her sister was pulled out from under a heavy armoire that had toppled. A ceiling collapsed in another house, and in other homes parts of exterior walls crumbled. Some stone walls along fields and local roads crumbled. Etna, the largest of Italy's three active volcanoes, has been particularly active since July. In recent days, Etna's latest eruption has been shooting volcanic ash, heavy smoke and lava stones into the air, coating roads and homes nearby with ash. A new fracture has opened near Etna's southeast crater and lava has been flowing down an uninhabited slope. The quake was also felt in the upscale Sicilian resort town of Taormina and in other towns in eastern Sicily. The Civil Protection agency said temporary shelters were being set up in gyms or municipal buildings for people whose houses were damaged or who were too frightened to return to their homes. Similar volcanic activity on Etna has been observed many times in past decades, Andrea Billi, a geologist with the state National Council of Research, told RaiNews24. This kind of activity "can last days or weeks," he said, "but it's unpredictable." Italy's Civil Protection chief said it appeared the activity at Etna was calming down. "From a scientific point of view, we're dealing with an isolated event," Angelo Borrelli told Sky TG24 TV. "The technical experts tell us we're heading toward a cooling of the lava, and we ought to expect a quiescence of the phenomenon (of earthquakes)." Some residents told reporters that after a similar quake in 1984 which killed a person, many on Mount Etna retrofitted their houses to enable them to withstand more powerful temblors. ___ Frances D'Emilio is on twitter at a href='http://www.twitter.com/fdemilio%3c'www.twitter.com/fdemilio/a
Example Output: Quake from Mount Etna volcano jolts Sicily, sparks panic.

Example Input: According to two studies published on Wednesday, DNA from these pre-modern humans may play a role in the appearance of hair and skin as well as the risk of certain diseases. Although Neanderthals became extinct 28,000 years ago in Europe, as much as one-fifth of their DNA has survived in human genomes due to interbreeding tens of thousands of years ago, one of the studies found, although any one individual has only about 2 percent of caveman DNA. "The 2 percent of your Neanderthal DNA might be different than my 2 percent of Neanderthal DNA, and it's found at different places in the genome," said geneticist Joshua Akey, who led one of the studies. Put it all together in a study of hundreds of people, and "you can recover a substantial proportion of the Neanderthal genome." Both studies confirmed earlier findings that the genomes of east Asians harbor more Neanderthal DNA than those of Europeans. This could be 21 percent more, according to an analysis by Akey and Benjamin Vernot, published online in the journal Science. Still, "more" is a relative term. According to the paper by geneticists at Harvard Medical School, published in Nature, about 1.4 percent of the genomes of Han Chinese in Beijing and south China, as well as Japanese in Tokyo come from Neanderthals, compared to 1.1 percent of the genomes of Europeans. Anthropologists expressed caution about the findings. Fewer than half a dozen Neanderthal fossils have yielded genetic material, said Erik Trinkaus of Washington University in St. Louis, one of the world's leading experts on early humans. Using this small sample to infer how much Neanderthal DNA persists in today's genome is therefore questionable, he said. As expected, since Neanderthals never existed in Africa, Africans and those who trace their ancestry to that continent have almost no Neanderthal DNA, the Harvard team found. Human ancestors began migrating out of humanity's natal continent as early as 1 million years ago, paleoanthropologists infer from fossil evidence, and between 500,000 and 200,000 years ago evolved into the robust, large-browed Homo neanderthalensis in Western Europe. Ever since scientists extracted DNA from the remains of Neanderthals, they have known that people today carry snippets of cavemen genes, in the amounts of 2 percent to 3 percent. That clinched the case that Neanderthals and modern humans interbred, probably 40,000 to 80,000 years ago, soon after the latter arrived in Europe from Africa. The new studies add details about how much DNA and of what kind we inherited. "The story of early human evolution is captivating in itself, yet it also has far-reaching implications for understanding the organization of the modern human genome," Irene Eckstrand of the National Institutes of Health's National Institute of General Medical Sciences, which partially funded the research, said in a statement. "Every piece of this story that we uncover tells us more about our ancestors' genetic contributions to modern human health and disease." The Harvard team used a novel genetic algorithm to estimate the probability that a particular genetic variant arose from Neanderthals. Basically, they started with the genome of a 50,000-year-old Neanderthal, and determined whether pieces of it also appeared in some non-Africans but not in sub-Saharan Africans. The algorithm identified remnants of Neanderthal DNA, called alleles, in genes associated with type 2 diabetes, Crohn's disease, lupus, biliary cirrhosis and smoking behavior. "But we can't tell if the Neanderthal alleles are contributing to disease," said Harvard's Sriram Sankararaman, lead author of the paper in Nature. Areas "with increased Neanderthal ancestry tend to be higher the farther away you go from genes," sitting, instead, in regions of the genome that do not actually produce the proteins, enzymes and other working molecules of the body. Neanderthal DNA does sit within some genes, however, such as those for keratin, a fibrous protein that makes skin, hair and nails tough and can be beneficial in colder environments by providing thicker insulation. The endurance of this Neanderthal DNA suggests that our caveman inheritance was adaptive, picked by natural selection to persist in our genome, generation after generation, because it conferred a survival advantage in individuals who carried it. The Harvard team analyzed the genomes of 1,004 people to estimate which populations got more or fewer Neanderthal DNA. Confirming a 2013 study, they found more in the genomes of east Asians than in Europeans. But they also dug deeper. Puerto Ricans and Spaniards have the least Neanderthal DNA, 1.05 percent and 1.07 percent respectively. That is curious because Neanderthals made their last stand on the Iberian peninsula, finally dying out there 28,000 years ago. Across all populations, Neanderthal DNA is conspicuously low in regions of the X chromosome and in testes-specific genes. The paucity of Neanderthal genes among those active in the testes suggests that interbreeding wasn't a resounding success: It produced viable children, but the males were infertile. Although as much as 20 percent of Neanderthal DNA persists in modern genomes, according to the Washington scientists, vast regions of the latter are Neanderthal deserts. Among them is a region of chromosome 7 that includes a gene called FOXP2. "FOXP2 has previously been implicated in speech and language and may be an example of a gene that influences a uniquely human trait, which is why we find no Neanderthal sequences in these regions," said Akey.
Example Output: Modern humans more Neanderthal than once thought, studies suggest.

Example Input: "Highly anticipated data for a Gilead Sciences Inc (GILD.O) experimental antiviral drug are expected later this month. Analysts are also awaiting results in the near-term for products already approved for other conditions from companies such as Roche Holding (ROG.S) and Regeneron Pharmaceuticals (REGN.O). While experts estimate an approved vaccine could be at least a year away, progress toward treatments that benefit some COVID-19 patients could help investors gauge when the epidemic could come under control and some economic activity might resume. "The more we see positive clinical data, the more investors will be comforted in the fact that this is a transitory issue like all epidemics are," said Art Hogan, chief market strategist at National Securities. Early signs of a slowdown in hospitalizations and intensive care needs in coronavirus hotspots in the United States and abroad have fed a stock market turnaround sparked by massive support from the Federal Reserve and a more than $2 trillion government bailout. As of Monday, the S&P 500 .SPX was off about 21% from its Feb. 19 all-time high but had rebounded 19% since March 23. "With each incremental piece of good news, that gets us closer to the end of the epidemic and the economic damage that falls in its wake," Hogan said. New York is nearing a plateau in the number of coronavirus patients hospitalized, Governor Andrew Cuomo said on Tuesday, even though the number of the deaths in the state hit a single-day high. Governments around the world have locked down their communities - urging citizens to stay inside and ordering restaurants, stores and other businesses shuttered - to contain the spread of COVID-19 cases, which have exceeded 1.4 million globally with over 80,000 deaths, according to a Johns Hopkins tally. Drugmakers are studying ways to combat the respiratory illness, for which there are no approved treatments, as hospitals face strains from the flood of patients. More than 330 clinical studies related to COVID-19 are listed in clinicaltrials.gov, a database maintained by the U.S. National Institutes of Health, including many seeking to test drugs already approved for other conditions. Gilead's remdesivir, which is administered intravenously, is one experimental treatment that has captured investors' attention. The biotechnology company's chief executive on March 28 said initial data would arrive in the ""coming weeks"" here and analysts said data could come in mid April. Remdesivir previously failed as a treatment for the Ebola virus. But it helped prevent disease and reduce severity of symptoms in monkeys infected with a virus more closely related to the new coronavirus in a study, raising hopes. Some analysts are cautioning against expecting that remdesivir will show an overwhelming benefit. Initial data are expected to come from studies of patients with relatively severe COVID-19. Because antivirals work best when patients are healthier, those results may show limited effectiveness, said Evan Seigerman, a biotech analyst at Credit Suisse. Even if remdesivir proves effective, the amount of the drug that would be available remains a concern. Gilead said last weekend here its existing supply could equate to more than 140,000 courses of treatment. Data is also anticipated for Regeneron (REGN.O) and Sanofi's (SASY.PA) Kevzara, perhaps by the end of the month, and for Roche's (ROG.S) Actemra - two similar rheumatoid arthritis drugs being tested for COVID-19 illness. Studies are also ongoing for hydroxychloroquine, a decades-old malaria drug that has been used by doctors for COVID-19 despite controversy over its effectiveness. "Just knowing that something works means investors can start thinking about the other side of this," said Keith Lerner, chief market strategist at Truist/SunTrust Advisory Services, in emailed comments to Reuters, "both from a human side and an economic and market perspective.""
Example Output:
Investors await data on coronavirus drugs as market rally builds.